Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVS Corvus Pharmaceuticals	$3.63 +3.7%	$3.71	$1.43 ▼ $10.00	$247.33M	0.71	641,938 shs	607,010 shs
ETON Eton Pharmaceuticals	$16.16 +1.1%	$14.07	$3.18 ▼ $18.41	$429.49M	1.34	177,817 shs	110,914 shs
IPSC Century Therapeutics	$0.49 -0.7%	$0.55	$0.34 ▼ $3.70	$42.51M	1.83	428,319 shs	227,715 shs
TNGX Tango Therapeutics	$1.37 -8.4%	$1.67	$1.11 ▼ $12.02	$147.57M	1.03	1.07 million shs	265,579 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVS Corvus Pharmaceuticals	-3.58%	+8.70%	+3.55%	-31.10%	+141.38%
ETON Eton Pharmaceuticals	+1.01%	+12.06%	+22.73%	-9.41%	+363.19%
IPSC Century Therapeutics	-0.82%	-7.85%	-2.98%	-41.11%	-82.72%
TNGX Tango Therapeutics	+2.05%	+7.97%	+1.36%	-52.24%	-79.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRVS Corvus Pharmaceuticals	2.373 of 5 stars	3.6	1.0	2.7	2.5	0.6
ETON Eton Pharmaceuticals	2.3691 of 5 stars	3.5	3.0	2.7	0.8	0.6
IPSC Century Therapeutics	1.9786 of 5 stars	3.5	1.0	2.4	1.7	0.6
TNGX Tango Therapeutics	2.2701 of 5 stars	3.5	0.0	3.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRVS Corvus Pharmaceuticals	3.25	Buy	$15.67	347.62% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$27.67	73.13% Upside
IPSC Century Therapeutics	3.00	Buy	$4.40	784.24% Upside
TNGX Tango Therapeutics	3.00	Buy	$12.33	727.74% Upside

Current Analyst Ratings Breakdown

Latest IPSC, ETON, CRVS, and TNGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/14/2025	TNGX Tango Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/3/2025	IPSC Century Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $2.00
3/28/2025	IPSC Century Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/26/2025	CRVS Corvus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$14.00 ➝ $15.00
3/26/2025	CRVS Corvus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/24/2025	IPSC Century Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $7.00
3/21/2025	IPSC Century Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
3/20/2025	IPSC Century Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$4.00 ➝ $2.00
3/19/2025	ETON Eton Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $26.00
3/19/2025	ETON Eton Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $24.00
3/19/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00

(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$0.79 per share	N/A
ETON Eton Pharmaceuticals	$39.01M	10.99	$0.00 per share	4,502.79	$0.60 per share	26.63
IPSC Century Therapeutics	$6.59M	6.50	N/A	N/A	$3.06 per share	0.16
TNGX Tango Therapeutics	$42.07M	3.83	N/A	N/A	$2.48 per share	0.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRVS Corvus Pharmaceuticals	-$27.03M	-$0.97	N/A	N/A	N/A	N/A	-70.71%	-45.90%	5/5/2025 (Estimated)
ETON Eton Pharmaceuticals	-$940K	-$0.15	N/A	31.96	N/A	-15.81%	-36.29%	-16.84%	5/8/2025 (Estimated)
IPSC Century Therapeutics	-$136.67M	-$1.63	N/A	N/A	N/A	-4,837.73%	-61.66%	-31.78%	5/8/2025 (Estimated)
TNGX Tango Therapeutics	-$101.74M	-$1.21	N/A	N/A	N/A	-284.42%	-49.64%	-32.00%	5/6/2025 (Estimated)

Latest IPSC, ETON, CRVS, and TNGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	TNGX Tango Therapeutics	-$0.34	N/A	N/A	N/A	$6.73 million	N/A
5/8/2025	Q1 2025	ETON Eton Pharmaceuticals	$0.05	N/A	N/A	N/A	$14.33 million	N/A
5/8/2025	Q1 2025	IPSC Century Therapeutics	-$0.31	N/A	N/A	N/A	N/A	N/A
5/5/2025	Q1 2025	CRVS Corvus Pharmaceuticals	-$0.12	N/A	N/A	N/A	N/A	N/A
3/25/2025	Q4 2024	CRVS Corvus Pharmaceuticals	-$0.12	-$0.18	-$0.06	-$0.18	N/A	N/A
3/19/2025	Q4 2024	IPSC Century Therapeutics	-$0.45	-$0.43	+$0.02	-$0.43	$0.67 million	$4.18 million
3/18/2025	Q4 2024	ETON Eton Pharmaceuticals	-$0.02	-$0.02	N/A	-$0.02	$10.53 million	$11.65 million
2/27/2025	Q4 2024	TNGX Tango Therapeutics	-$0.32	-$0.35	-$0.03	-$0.35	$7.84 million	$4.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRVS Corvus Pharmaceuticals	N/A	0.92	0.92
ETON Eton Pharmaceuticals	N/A	1.51	1.41
IPSC Century Therapeutics	N/A	10.39	10.39
TNGX Tango Therapeutics	N/A	8.00	8.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRVS Corvus Pharmaceuticals	46.64%
ETON Eton Pharmaceuticals	27.86%
IPSC Century Therapeutics	50.20%
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
CRVS Corvus Pharmaceuticals	31.30%
ETON Eton Pharmaceuticals	14.89%
IPSC Century Therapeutics	6.80%
TNGX Tango Therapeutics	6.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRVS Corvus Pharmaceuticals	30	68.14 million	44.15 million	Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.17 million	Optionable
IPSC Century Therapeutics	170	86.05 million	79.25 million	Optionable
TNGX Tango Therapeutics	90	108.11 million	100.65 million	Optionable

IPSC, ETON, CRVS, and TNGX Headlines

Recent News About These Companies

Blue Owl Capital Holdings LP Acquires New Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)

April 26 at 6:43 AM | marketbeat.com

Trv Gp Vi LLC Acquires New Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX)

April 22, 2025 | marketbeat.com

Gilead Sciences Inc. Acquires Shares of 4,854,443 Tango Therapeutics, Inc. (NASDAQ:TNGX)

April 20, 2025 | marketbeat.com

Brokerages Set Tango Therapeutics, Inc. (NASDAQ:TNGX) PT at $12.33

April 19, 2025 | americanbankingnews.com

HC Wainwright Brokers Reduce Earnings Estimates for TNGX

April 18, 2025 | marketbeat.com

Q1 Earnings Forecast for TNGX Issued By HC Wainwright

April 17, 2025 | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of "Buy" from Analysts

April 16, 2025 | marketbeat.com

HC Wainwright Reiterates Buy Rating for Tango Therapeutics (NASDAQ:TNGX)

April 16, 2025 | marketbeat.com

Barbara Weber, M.D., Elected to ITM Supervisory Board

April 9, 2025 | markets.businessinsider.com

Tango Therapeutics cuts nearly one-fifth of staff

April 8, 2025 | biopharmadive.com

Schroder Investment Management Group Makes New Investment in Tango Therapeutics, Inc. (NASDAQ:TNGX)

April 8, 2025 | marketbeat.com

Short Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Expands By 29.4%

April 1, 2025 | marketbeat.com

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at [...]

March 25, 2025 | aktiencheck.de

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

March 25, 2025 | globenewswire.com

Barclays Sticks to Its Buy Rating for Tango Therapeutics (TNGX)

March 24, 2025 | markets.businessinsider.com

Tango Therapeutics (TNGX) Receives a Buy from Barclays

March 1, 2025 | markets.businessinsider.com

Tango Therapeutics Advances Cancer Treatment Pipeline

February 28, 2025 | tipranks.com

Tango Therapeutics sees cash runway into 3Q26

February 27, 2025 | markets.businessinsider.com

Tango Therapeutics reports Q4 EPS (35c), consensus (34c)

February 27, 2025 | markets.businessinsider.com

Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates

February 27, 2025 | zacks.com

Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights

February 27, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC, ETON, CRVS, and TNGX Company Descriptions

Corvus Pharmaceuticals NASDAQ:CRVS

$3.63 +0.13 (+3.71%)

As of 02:09 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Eton Pharmaceuticals NASDAQ:ETON

$16.16 +0.18 (+1.12%)

As of 02:09 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Century Therapeutics NASDAQ:IPSC

$0.49 0.00 (-0.72%)

As of 02:09 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Tango Therapeutics NASDAQ:TNGX

$1.36 -0.13 (-8.39%)

As of 02:09 PM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time